Journal profile · Pharmacology & Pharmacy
Pharmacogenomics
ISSN 1462-2416 · eISSN 1744-8042 · Future Medicine Ltd. · ENGLAND · Bimonthly
Pharmacogenomics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.62; hybrid open access; median 84 days to acceptance (101 articles, last 24 months); community-reported acceptance: fairly easy; 72 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacogenomics is published by Future Medicine Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms and Genetic Associations and Epidemiology, together about 40.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics28.1%
- Drug Transport and Resistance MechanismsMedicine6.5%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology5.8%
- Pharmaceutical studies and practicesMedicine4.7%
- Computational Drug Discovery MethodsComputer Science3.7%
- Genomics and Rare DiseasesBiochemistry, Genetics and Molecular Biology3.7%
- Pharmacological Effects and Toxicity StudiesMedicine3.6%
- Gene expression and cancer classificationBiochemistry, Genetics and Molecular Biology3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.62LetPub ·
- CiteScore 2026-06
- 3LetPub ·
- SJR 2026-06
- 0.41LetPub ·
- SNIP 2026-06
- 0.49LetPub ·
- h-index
- 83LetPub ·
- h-index
- 113OpenAlex ·
- i10-index
- 2,035OpenAlex ·
- 2-year mean citedness
- 1.98OpenAlex ·
- Self-citation rate
- 12.5%LetPub ·
- Share of gold OA articles
- 7.33%LetPub ·
Volume
- Articles per year
- 66LetPub ·
Articles by year OpenAlex count · 3,740 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 44 | 33 | 12 |
| 2025 | 72 | 62 | 128 |
| 2024 | 63 | 49 | 215 |
| 2023 | 103 | 27 | 468 |
| 2022 | 91 | 27 | 637 |
| 2021 | 109 | 34 | 1,091 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
84 daysMedian, submission to acceptance · P25–P75 57 days – 117 days
- Acceptance to online
- median 10 days (101 articles)
- Submission to online
- median 99 days
- Sample
- 101 articles with submission and acceptance dates (129 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Future Medicine Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 1462-2416
- Electronic ISSN
- 1744-8042
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Pharmacogenomics
What CAS zone is Pharmacogenomics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacogenomics is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacogenomics?
The latest impact factor listed by LetPub is 1.62; CiteScore 3, h-index 113.
How long does peer review take at Pharmacogenomics?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 84 days (interquartile range 57–117 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Pharmacogenomics?
According to LetPub and DOAJ records, Pharmacogenomics is indexed in SCIE and Scopus.
Is Pharmacogenomics open access, and what is the APC?
Pharmacogenomics is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .